• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Dapagliflozin efficacious and safe in treating heart failure

byDavid XiangandHarsh Shah
May 13, 2022
in Cardiology, Chronic Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death regardless of frailty status.

2. Dapagliflozin improved quality of life and physical function regardless of frailty status.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Frailty is defined as increased vulnerability to endogenous and exogenous stressors due to loss of homeostatic reserves across several physiologic systems, leading to poor health outcomes. In relation to heart failure, patients with heart failure (HF) are up to 6 times more likely to be frail than the general population, and frail persons may be at a higher risk for developing HF. Frail patients with HF also have a higher risk for death, hospitalizations, and functional decline than non-frail patients with HF. However, there is a gap in knowledge as to whether new HF treatments are effective and safe in frail patients, as frail patients may have reduced tolerance to treatments, experience more adverse drug reactions, have poorer adherence, and be more likely to discontinue treatment than non-frail patients. This study demonstrated the efficacy and safety of dapagliflozin in patients with heart failure with reduced ejection fraction, regardless of frailty status. This study was limited by enrollment criteria that precluded the inclusion of very high-risk patients. Nevertheless, these study’s findings are significant, as they demonstrate that regardless of frailty status, dapagliflozin significantly improved all outcomes examined in patients with heart failure, such as the risk of worsening heart failure or cardiovascular death.

Click to read the study in AIM

Relevant Reading: Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin

In-Depth [randomized clinical trial]: This post hoc analysis of phase 3 randomized clinical trial examined 4742 patients from a randomized, double-blind, placebo-controlled trial in patients with heart failure with reduced ejection fraction (HFrEF). Patients with a diagnosis of HF for at least 2 months, a left ventricular ejection fraction (LVEF) of 40% or less, and an N-terminal pro-B-type natriuretic peptide concentration of 600 pg/mL or more if hospitalized for HF within the previous 12 months were eligible for the study. Patients who had symptomatic hypotension, systolic blood pressure lower than 95 mm Hg, acute decompensated HF, or hospitalization due to decompensated HF fewer than 4 weeks before enrollment were excluded from the study. The primary outcome measure was the composite of worsening HF (HF hospitalization or an urgent visit for worsening HF and administration of intravenous therapy) or cardiovascular death. Outcomes in the primary analysis were assessed via the Kaplan-Meier estimator, the Aalen-Johansen estimator, and Cox proportional hazards models. Based on the analysis, dapagliflozin reduced the risk for worsening HF or cardiovascular death across all frailty status classes: the hazard ratios from lowest to highest class were 0.72 (95% Confidence Interval [CI], 0.59 to 0.89), 0.77 (95% CI, 0.62 to 0.97), and 0.71 (95% CI, 0.54 to 0.93). The number of patients who needed to treat to prevent 1 primary event per 100 person-years was 31, 25, and 15 in the lowest to highest frailty class, respectively. Dapagliflozin also significantly improved symptoms, physical function, and quality of life, regardless of frailty class. The absolute reductions in clinical events and improvements in health status were also generally larger in the frailest patients. Overall, this study demonstrates that dapagliflozin reduced the risk for worsening HF events, cardiovascular death, and all-cause death, and improved symptoms, physical function, and quality of life, regardless of the level of frailty in patients with HFrEF, also leading to larger absolute reductions in clinical events in more frail patients.

RELATED REPORTS

Virtual yoga and meditation intervention may be associated with increased health-related quality of life

Interatrial shunt device not effective in patients with symptomatic heart failure

#VisualAbstract: Implementing a ban on commercial indoor tanning across England would be both cost-effective and life-saving

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascular deathdapagliflozinfrailtyheart failureHFrEF (heart failure with reduced ejection fraction)physical functionquality of life
Previous Post

Nasal high-flow therapy improves likelihood of neonatal intubation

Next Post

Canadian Syncope Risk Score demonstrates international external validation

RelatedReports

Exercise intervention linked to reduced functional decline among elderly patients admitted to the hospital
Wellness

Virtual yoga and meditation intervention may be associated with increased health-related quality of life

May 20, 2022
30-Day mortality decreased in UK pediatric cardiac surgery from 2000-2010
Cardiology

Interatrial shunt device not effective in patients with symptomatic heart failure

March 29, 2022
#VisualAbstract: Implementing a ban on commercial indoor tanning across England would be both cost-effective and life-saving
StudyGraphics

#VisualAbstract: Implementing a ban on commercial indoor tanning across England would be both cost-effective and life-saving

February 24, 2022
Patient Basics: Hip Fracture
Emergency

Cemented hemiarthroplasty improves quality of life for intracapsular hip fracture patients

February 21, 2022
Next Post
Epileptogenic foci may be lateralized using functional brain glutamate imaging

Canadian Syncope Risk Score demonstrates international external validation

Masks for personal protection for SARS-CoV-2 infection

Adding mask recommendation did not significantly reduce the SARS-CoV-2 infection rate

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

BNT162b2 safe and efficacious in children 5 to 11 years of age

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.